Article

Identification and characterization of new impurities in rivastigmine.

APL Research Centre, Hyderabad, India.
Pharmazie (impact factor: 1.01). 05/2010; 65(5):336-8. pp.336-8
Source: PubMed

ABSTRACT Rivastigmine is a drug against Alzheimer's disease, and is a non-pharmacopoeial compound. During the preparation of rivastigmine in our laboratory, two impurities were detected and identified with a simple and sensitive reversed-phase liquid chromatography coupled with electrospray-mass spectrometry. The same impurities were also observed in commercial batches. These impurities were isolated by preparative HPLC and co-injected with rivastigmine sample to confirm the retention times in HPLC. These impurities were characterized as N,N-dimethyl-3-[1-dimethylaminoethyl]phenylcarboxylate (dimethyl-rivastigmine) and N,N-diethyl-3-[1-dimethylaminoethyl]phenylcarboxamide (diethyl-rivastigmine). Structural elucidation of these impurities by spectral data (1H NMR, 13C NMR and MS) is discussed.

0 0
 · 
1 Bookmark
 · 
119 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

commercial batches
 
electrospray-mass spectrometry
 
impurities
 
non-pharmacopoeial compound
 
preparative HPLC
 
rivastigmine sample
 
sensitive reversed-phase liquid chromatography
 
spectral data
 
Structural elucidation